MRUS: Why Wells Fargo’s downgrade could be a golden chance!

Company Overview & Recent Developments

Merus N.V. (NASDAQ: MRUS) is a Netherlands-based oncology biotech specializing in multispecific antibodies for cancer. The company’s pipeline has gained significant traction, highlighted by its lead candidate petosemtamab (MCLA-158) – a biclonal antibody targeting EGFR and LGR5 – which is in two Phase 3 trials for head and neck cancer (^[1]). Interim Phase 2 data have been very encouraging: Merus reported a 63% tumor response rate and 79% 12-month survival in first-line head & neck patients when petosemtamab was combined with pembrolizumab (Keytruda) (^[1]). This “unprecedented efficacy” at ASCO 2025 drove enthusiasm among clinicians and analysts (^[1]). Merus is also evaluating petosemtamab in metastatic colorectal cancer (mCRC), with initial colon cancer data expected in the second half of 2025 (^[2]) – a potential new frontier given LGR5’s role in colon tumors.

Beyond petosemtamab, Merus achieved a major milestone in late 2024: the FDA approved its antibody zenocutuzumab (brand name Bizengri®) for patients with cancers harboring NRG1 gene fusions (^[2]). This made Bizengri the first approved therapy for certain lung and pancreatic cancers with this rare mutation (^[3]). While the NRG1-fusion population is small (analysts project global peak sales of only ~$460 million for Bizengri (^[3])), the approval validates Merus’s technology. Merus promptly licensed U.S. commercialization of Bizengri to Partner Therapeutics (PTx) (^[4]) (^[5]), bringing in upfront revenue and allowing Merus to focus on petosemtamab’s development. The company has also attracted collaborations with large pharma – for example, Eli Lilly is co-developing up to three bispecific T-cell engagers using Merus’s Biclonics® platform (^[2]), and Merus retains global rights to another antibody (MCLA-129) outside a partnership in China (^[2]). These partnerships underscore the breadth of Merus’s pipeline and provide non-dilutive funding through milestones. Overall, Merus has transformed from a clinical-stage hopeful into a biotech with an FDA-approved product and a potential blockbuster in late-stage trials, which has not gone unnoticed by bigger players.

Genmab Deal: In fact, on September 29, 2025, Danish pharma Genmab announced an agreement to acquire Merus for $97.00 per share in cash, valuing Merus at ~$8.0 billion (^[6]) (^[6]). This represents a 41% premium to MRUS’s prior trading price (around $68 on Sept 26) (^[7]). Genmab’s interest is squarely in petosemtamab – a late-stage asset that received two FDA Breakthrough Therapy designations and could complement Genmab’s oncology portfolio (^[6]) (^[6]). The deal has been unanimously approved by both companies’ boards and is expected to close by early Q1 2026 via a tender offer (^[6]). Merus’s stock price predictably jumped on the news, closing in the mid-$90s, near the offer price. This sequence of events is crucial context for the recent Wells Fargo downgrade and others – the stock’s rapid appreciation and a de-facto price cap at $97 prompted many analysts to temper their ratings in the short term. However, as we’ll explore, the downgrade may reflect timing and valuation optics rather than a change in Merus’s fundamental prospects.

Dividend Policy & Shareholder Returns

Merus is a growth-stage biotech and, as is typical for the sector, it does not pay any dividend. Since its inception, Merus has never declared cash dividends and has stated it intends to reinvest any future earnings back into the business (^[8]) (^[8]). In other words, shareholders’ returns hinge entirely on stock price appreciation (or a buyout), not income distributions. The dividend yield is 0%, and management has explicitly guided that no dividends are expected in the foreseeable future (^[8]) (^[8]). This policy is prudent given Merus’s ongoing R&D needs and lack of sustainable profits. Investors in MRUS should be comfortable with a total-return strategy, where value is driven by clinical milestones and pipeline success rather than near-term cash flow. (Metrics like AFFO/FFO, used for REITs and other income stocks, are not applicable here – Merus generates net losses and negative free cash flow as it funds drug development, rather than funds-from-operations.) The upside for shareholders comes from capital gains, such as the substantial appreciation MRUS saw over the past year. For perspective, Merus traded around $41.50 in early 2025 (^[9]); by late September, positive trial results and takeover speculation had propelled the stock into the $90s, more than doubling its value in under a year. Such growth, while volatile, is the primary “shareholder return” for a biotech like Merus – now crystallized by Genmab’s $97/share acquisition offer.

Financial Position & Leverage

Merus’s balance sheet is robust after a mid-2025 capital raise, and the company carries minimal debt. In June 2025, Merus took advantage of its surging stock price to issue equity, raising $345 million gross in a public offering (^[1]). As a result, cash and investments swelled to roughly $710 million by mid-year 2025, up from $536 million at 2024 year-end (^[1]). Management noted that, under its current operating plan, this cash “is expected to fund operations at least into 2028.” (^[1]) In other words, Merus had secured a multi-year runway, alleviating the need for near-term financing. This is a significant strength – many biotechs face cash crunches or dilution risk, but Merus positioned itself to self-fund Phase 3 trials and potential commercialization for petosemtamab.

Crucially, Merus has no outstanding interest-bearing debt on its books (^[8]). The company has financed its growth primarily through equity raises and collaboration payments, avoiding bank loans or convertible notes. An SEC filing confirms Merus had no debt as of the end of 2023 (^[8]), and that remained true through 2025. Apart from modest lease liabilities and deferred revenue from partnerships, the capital structure is unleveraged, which eliminates credit risk and interest expenses. Consequently, leverage ratios are low and interest coverage is a non-issue (Merus actually earns interest on its cash holdings rather than paying it out). There are no major debt maturities or refinancing needs on the horizon – a positive for equity holders. The strong cash position also enabled Merus to invest aggressively in R&D (the company’s R&D expense more than doubled from 2022 to 2024 (^[10])) while still extending its cash runway. In short, Merus entered the Genmab deal from a position of financial strength: a cash-rich, debt-free balance sheet. If the acquisition closes, Merus shareholders will be cashed out at $97. But had Merus remained independent, it appeared well-funded to advance its pipeline without immediate dilution. This lack of leverage not only reduces financial risk but also gave Merus strategic flexibility – for instance, to negotiate from strength in partnering or buyout discussions (as evidenced by the favorable all-cash offer).

Pipeline & Growth Prospects

Merus’s growth outlook is dominated by petosemtamab, a potentially paradigm-shifting therapy for solid tumors. Petosemtamab is a bispecific antibody that targets EGFR (a well-known cancer growth receptor) and LGR5 (a stem cell marker) simultaneously. This novel mechanism has shown striking efficacy in head and neck squamous cell carcinoma (HNSCC), an aggressive cancer where survival outcomes have plateaued in recent years. In a Phase 2 trial for first-line recurrent/metastatic HNSCC, petosemtamab + Keytruda delivered a 63% objective response rate and 79% one-year survival, far exceeding historical results of Keytruda alone (^[1]). Based on these results, two Phase 3 trials (LiGeR-HN1 in 1L HNSCC and LiGeR-HN2 in 2L/3L HNSCC) are underway and expected to fully enroll by end of 2025 (^[1]) (^[2]). The FDA granted Breakthrough Therapy status to petosemtamab in HNSCC (actually two BTDs, likely for different settings) (^[6]), which speaks to the unmet need and the promising early data. If Phase 3 confirms the benefit, petosemtamab could become a new standard of care in HNSCC, potentially combined with PD-1 immunotherapy as the data suggest.

The big open question – and opportunity – is whether petosemtamab’s efficacy extends to other cancers. Merus is actively testing it in metastatic colorectal cancer (mCRC), another EGFR-expressing tumor type where LGR5 is often upregulated. Trials are evaluating petosemtamab in 1st- and 2nd-line mCRC (with chemo) and as 3rd-line monotherapy (^[2]). Initial mCRC clinical data are anticipated in late 2025 (^[2]). Success in colon cancer would unlock a much larger market than head & neck – tens of thousands of patients annually – albeit the bar for efficacy is also high in CRC. Wells Fargo’s analyst specifically highlighted “untapped potential” for petosemtamab in mCRC when initiating coverage (^[9]), suggesting that positive colon data could meaningfully boost Merus’s long-term value. This is a key catalyst on the horizon.

Meanwhile, Merus has other pipeline assets contributing to its growth story. Zenocutuzumab (Bizengri), though serving a niche population, established Merus’s ability to take a drug from research to FDA approval (^[2]). Bizengri treats tumors with NRG1 fusions – rare genetic drivers found in ~0.2% of pancreatic and lung cancers. FDA approval in Dec 2024 (after Breakthrough designation and an accelerated review) made Bizengri the first-ever therapy for NRG1+ lung and pancreatic cancer (^[3]). Merus wisely partnered with Partner Therapeutics to commercialize Bizengri in the U.S. (^[5]), securing a $13.3 million initial supply sale and ongoing royalties (^[1]) (^[1]). While Bizengri’s revenue might only be tens of millions annually (small relative to Merus’s valuation), it provides a proof-of-concept for Merus’s platforms and could contribute royalty income if uptake grows. Analysts at RBC estimate peak global Bizengri sales of about $462 million (^[3]) – meaningful, but still eclipsed by the blockbuster potential of petosemtamab if it succeeds.

Don't wait — first dividend checks could arrive any day.

Get the concise guide to start collecting royalty checks now.

Get Instant Access
✕

Merus’s earlier-stage programs also warrant mention, as they add optionality. MCLA-129 is a bispecific antibody targeting EGFR and c-MET (implicated in lung and other cancers); Merus is developing it globally while partner Betta Pharmaceuticals handles China (^[2]). This drug showed initial signs of activity in NSCLC (including MET-mutant cases) in a Phase 1 trial, and further studies are ongoing (^[11]). Additionally, Merus’s proprietary Biclonics® technology – which enables full-length bispecific antibodies – has attracted alliances with major players. A global collaboration with Eli Lilly is exploring up to three T-cell redirecting bispecific antibodies for oncology (^[2]). Merus received upfront payments and research funding, and could earn milestones if Lilly advances any programs. A separate alliance with Biohaven is focused on next-generation antibody-drug conjugates (ADCs) using Merus’s bispecific platform (^[2]). While these partnered programs are in preclinical stages, they validate Merus’s scientific platform and could yield long-term upside (or at least non-dilutive capital) if successful. In summary, Merus’s growth prospects are anchored by petosemtamab’s near-term potential in HNSCC (and possibly CRC), augmented by breadth in its pipeline (Bizengri’s niche market, plus multiple earlier programs backed by partnerships). This multi-layered pipeline is a central reason why Genmab was willing to pay $8 billion – it’s not just buying one drug, but also Merus’s antibody engineering expertise and future candidates.

Valuation & Analyst Sentiment

Valuing a biotech like Merus requires focusing on future potential rather than current earnings. Traditional metrics (P/E, EV/EBITDA, P/FFO) are not meaningful for MRUS at this stage – the company has negative earnings and does not generate positive operating cash flow (^[8]). Instead, investors and analysts assess Merus on pipeline-adjusted metrics: clinical success probabilities, peak sales forecasts, and strategic value to acquirers. At the $97/share offer price, Merus’s equity is valued around $7.1 billion (for ~73 million shares outstanding (^[1])). Net of ~$0.7 billion in cash, the enterprise value is roughly $6.4 billion. This is a lofty figure relative to Merus’s trailing revenue (~$35 million in H1 2025 (^[1])) – over 100× annualized sales, reflecting the reality that most of Merus’s value lies in drugs that are not yet on the market. For context, even if Bizengri reaches the optimistic peak of ~$462 million sales (as projected by RBC) (^[3]), that would justify only a fraction of the valuation (perhaps ~$1–2 billion of value using typical pharma multiples). The bulk of the $6–8 billion implied value is attributable to petosemtamab’s anticipated future sales in HNSCC (and potentially CRC or other tumors). If petosemtamab achieves multi-billion-dollar annual revenue as a first-line cancer therapy, the valuation makes sense; if it were to fail in Phase 3, the valuation would collapse. This binary nature is common in biotech – pricing is essentially a probability-weighted bet on a pipeline’s success.

Analyst sentiment on MRUS has shifted in the wake of its rapid stock rise and the Genmab deal. Until recently, many analysts were bullish: for example, Wells Fargo initiated coverage in February 2025 with an “Overweight” rating and a $91 target, citing petosemtamab’s strong position in mCRC as a key upside driver (^[9]). As the stock rallied through the $80s and $90s, several firms raised their price targets substantially. Canaccord Genuity, for instance, lifted its target from $67 to $97 (while maintaining a Hold rating) in late September (^[12]). Barclays initiated coverage on Sept 17, 2025 with an Overweight rating and a Street-high $112 target (^[12]), reflecting confidence in Merus’s long-term prospects beyond the then-current price. However, after Genmab’s $97 offer was announced, the upside became capped in the near term – leading to a wave of downgrades. On Sep 29, Wells Fargo downgraded MRUS to “Equal Weight” (hold), setting a $97 target (up from $95 prior) to align with the buyout price (^[13]). Similarly, Citigroup cut its rating from Buy to Neutral and trimmed its target to $97 (from $101) (^[12]); William Blair pulled back from Strong Buy to Hold (^[12]); and Truist and Needham reportedly downgraded from Buy to Hold as well (^[13]). In effect, once MRUS stock was trading around ~$94–95 (within a few percent of the offer), analysts moved to the sidelines – a logical response since arbitrage to $97 represented only ~3% upside at that point (^[12]).

Today, consensus analyst ratings characterize Merus as a Hold, purely due to valuation. According to MarketBeat data, 4 analysts rate MRUS a Buy and 12 rate it Hold, with an average price target of $92.88 (^[12]) (essentially in line with the current market price in the low-to-mid $90s). This consensus reflects the broad agreement that Merus’s fundamentals are sound, but the stock is fairly priced after its >100% run-up and the pending acquisition. It’s noteworthy that a few analysts still see more value – e.g. Barclays’ $112 target and Guggenheim’s ~$109 target (maintained even after the PTx partnership news) (^[9]) – implying that they view $97 as a relatively conservative takeout price. These outliers suggest that if petosemtamab delivers on its promise (especially in additional indications), Merus could have been worth considerably more in the long run. However, for most on Wall Street, the Genmab deal now defines the valuation ceiling. Wells Fargo’s downgrade encapsulates this sentiment: it was not a call on deteriorating science or financials, but a recognition that the stock’s risk/reward is balanced at ~$95 given an offer on the table (^[13]). In sum, MRUS’s valuation is high by conventional measures but is underpinned by petosemtamab’s high-reward potential – and the recent analyst moves are primarily about short-term price alignment, not a vote of no confidence in the company’s assets.

Risks & Red Flags

Every investment in a clinical-stage biotech carries significant risks, and Merus is no exception. Here are key risk factors and red flags to consider:

– Clinical & Regulatory Risk: The foremost risk is that petosemtamab could fail to confirm its early results in Phase 3. Drug development is a lengthy, expensive process with an uncertain outcome (^[1]). Unforeseen issues (lower efficacy in a broader population, safety signals, etc.) could derail approval. Given Merus’s valuation rests largely on petosemtamab, a trial failure or regulatory setback would have a devastating impact on the stock. Even with Breakthrough Therapy status, the bar for FDA approval is high – success is not guaranteed until robust Phase 3 data are in hand.

– Single-Asset Dependence: Merus now trades at a multi-billion valuation essentially on one asset. This concentration is a classic red flag – if anything goes wrong with petosemtamab’s development or market uptake, Merus has no other comparably large revenue source to fall back on. Bizengri’s niche sales and early-stage projects are not enough to justify the valuation alone. This binary dependence (petosemtamab vs. bust) amplifies the stock’s risk profile.

– Competition and Market Adoption: While petosemtamab’s data in HNSCC are impressive, Merus will eventually face competition from other therapies. EGFR is an established target (e.g. Erbitux is used in head & neck cancer), and PD-1 inhibitors are standard – Merus must convince oncologists that a dual-target antibody adds significant benefit. Large companies could develop alternative immunotherapies or bispecifics for HNSCC or CRC. If a superior or cheaper treatment emerges, petosemtamab’s commercial potential could be eroded. Additionally, market adoption in CRC (if data are positive) may depend on biomarker factors or combination strategies that are still uncertain.

– Financial Burn Rate: Although Merus raised substantial cash, it also spends heavily on R&D and will likely continue to burn ~$250+ million per year at its current pace (several Phase 3 trials in parallel). If the company remained independent and petosemtamab reached approval, Merus would face the expense of commercialization (sales force, marketing) unless partnered – potentially requiring more cash. Any delays or trial expansions could increase expenditures and eventually force the company to seek additional funding (diluting shareholders or taking on debt). The recent deal somewhat alleviates this concern (Genmab would foot the costs), but it’s a risk that existed for Merus as a standalone entity.

– Deal Closure Risk: Merus’s near-term stock price is now tied to the Genmab acquisition. While the deal has been approved by both boards, it must still pass conditions – including a tender of a majority of shares and regulatory clearances (^[6]). There is a risk (albeit seemingly low) that the acquisition could be delayed or even fail (for example, if not enough shareholders tender or an unforeseen antitrust issue arises). If the deal were to fall through, MRUS shares could plunge back toward pre-deal levels. The $97 offer price was ~41% above the late-September trading price (^[7]), so one can infer a roughly one-third downside risk if Merus returns to the mid-$60s without the M&A support. For investors buying now in hopes of arbitrage or a higher bid, this risk is important. Essentially, MRUS has a hard floor at $97 as long as the deal is expected to close – but if that expectation changes, the floor is removed.

– No-Shop & Competing Bids: Typically, once a merger agreement is in place, the company is bound by no-shop provisions, limiting its ability to seek other offers. Barring an unsolicited superior bid, Merus is unlikely to get a higher price now. The lack of competing bidders could be seen as a signal that $97 was already a full valuation. If another interested pharma does emerge, it would be an unexpected positive – but absent that, the upside beyond $97 is capped while the downside is asymmetrical if the deal breaks. Investors should not assume a bidding war will bail them out.

Overall, Merus’s risk profile is high – in line with most clinical biotechs with a single lead product. The intensifying focus on petosemtamab means “all eggs are in one basket.” Moreover, current shareholders face the unique interim risk of the merger arbitrage spread: MRUS trades just below $97, reflecting a small discount until closing. That gap could widen on any hints of trouble closing the deal. It’s crucial to recognize that while the Wells Fargo downgrade and others were not due to new negatives about Merus’s science, they do underscore that the easy money has been made – the stock is no longer undervalued by consensus, and in the short term it behaves more like a merger arbitrage bet than a pure growth stock.

Open Questions & Outlook

Despite the risks, there are optimistic open questions that hint at further opportunity – the crux of why a downgrades-driven dip might be a “golden chance” for certain investors:

– Will the Genmab Acquisition Complete Smoothly? All signs point to yes – Genmab has financing lined up (including $5.5 billion from Morgan Stanley) (^[7]) and strategic rationale to close the deal. The transaction is expected to wrap up by early Q1 2026 (^[6]). If one is investing at ~$94 today, the base-case outlook is a ~3% gain upon deal closing in a few months, which is a modest but low-risk return relative to typical biotech volatility. The open question is more for existing holders: should one tender shares or wait? If you believe another bidder might surface or that Merus is worth more than $97, holding out could be considered – but that would be speculating on a very slim probability. As of now, no higher offer has emerged, and Merus’s board has endorsed Genmab’s bid.

– Is $97 a Fair Price or a Steal? Some analysts clearly thought Merus could be worth more (as evidenced by targets above $100 (^[12])). Genmab itself must believe petosemtamab’s long-term revenue could justify well above $8 billion in value, or else it wouldn’t pursue this deal. If Phase 3 trials succeed and petosemtamab expands to additional cancers, Genmab may end up with a blockbuster on its hands – potentially making $97/share look cheap in hindsight. This raises an open question for investors: does the market underappreciate Merus’s pipeline? For those who see petosemtamab as a potential multi-indication therapy (HNSCC, CRC, maybe more), the Wells Fargo “Hold” rating and short-term price cap could be a golden opportunity to invest alongside Genmab’s conviction. Essentially, one can piggyback on Genmab’s due diligence – the acquirer is a sophisticated antibody company known for successes like Darzalex, and it’s voting with $8 billion that Merus’s science is sound. If you trust Genmab’s judgment and you’re able to buy MRUS slightly below the deal price, you either gain a small arbitrage profit at closing or, in the unlikely scenario the deal fails, you retain ownership of Merus which you believed was undervalued to begin with. (Of course, the risk is that if the deal fails, the market may severely mark down Merus, testing your conviction.)

– How Will Petosemtamab’s Story Unfold from Here? Investors should watch for upcoming clinical readouts. The next major inflection could be those initial mCRC trial results in late 2025 (^[2]). Positive data in colon cancer would not affect the merger outcome (the price is set), but it could affect how the market perceives the value of petosemtamab (increasing the odds that Genmab got a bargain). Conversely, if colon data disappoint, it might validate the cautious stance of those who downgraded MRUS, suggesting that $97 was fair or even generous for just the HNSCC opportunity. Additionally, by mid-to-late 2026 Genmab/Merus might have interim Phase 3 data in HNSCC – success there could lead to filings for approval. An open question is how quickly petosemtamab could reach the market. Merus indicated it was engaging regulators about potential Biologics License Applications (BLAs) as early as 2024 for another program (^[8]), and with two BTDs in hand, one wonders if an accelerated approval path for petosemtamab could be on the table if data are strong. Under Genmab’s ownership, the resource and experience to expedite development will be there. For current MRUS stakeholders (at least until the deal closes), every data release is a pivotal moment that could sway arbitrage spreads or simply offer the satisfaction of seeing the science validated.

– What About Merus’s Other Assets? Post-acquisition, these become Genmab’s concern, but they’re still relevant to the fuller picture. Will Genmab continue Merus’s partnerships (Lilly, Biohaven, etc.) or could there be buyout of collaboration programs? For example, if Eli Lilly likes a bispecific candidate from the collab, might Genmab negotiate to license it fully? These are longer-term questions that don’t impact MRUS stock directly now, but they underscore that Merus’s platforms had more to offer. Open questions also remain on Bizengri’s commercial trajectory – Partner Therapeutics has launched it (likely in early 2025 after approval), but how many patients will be identified and treated? The initial uptake could influence modest royalty streams in 2025–2026. Any significant shortfall or growth there is more informative for Genmab’s balance sheet than MRUS at this point, but it speaks to Merus’s legacy product performance.

Looking ahead, the outlook for MRUS investors is now largely binary and time-limited: either the Genmab deal closes and you receive cash, or it doesn’t and Merus continues as an independent biotech. In either scenario, Merus’s underlying science will progress – now with a larger company at the helm – and the ultimate success or failure of its drugs will become clear in the coming years. The recent analyst downgrades should be viewed in this context. They are not bearish calls on Merus’s technology; rather, they reflect that Merus’s valuation caught up to (or, via the buyout, was locked into) its near-term potential. For a long-term believer, this pullback to the low-$90s (off a speculative peak and post-downgrade knee-jerk selling) could indeed represent a “golden chance” – an opportunity to invest on the same terms as a leading oncology company (Genmab) before petosemtamab’s true value is proven out. However, that opportunity comes with lots of baggage: minimal upside unless a new twist occurs, and significant downside if things go awry.

In summary, Wells Fargo’s move to Equal Weight and similar downgrades mark a turning point where Merus is no longer an under-the-radar outperform idea, but a company in transition (pending M&A). Investors must decide if they want to stick around for the final chapter – taking the sure $97 per share (less any spread) if the deal goes through – or if they believe the story of petosemtamab is worth betting on beyond that, in which case any wobble in stock price now could be a buying opportunity. The fact that a sophisticated firm like Genmab is eager to pay billions for Merus’s assets is a strong vote of confidence in the science (^[6]). That confidence, juxtaposed against a raft of cautious “Hold” ratings, creates a scenario where contrarian investors might find their golden opportunity. As always, one should weigh the risk-reward carefully: the downgrades tell us the easy gains are realized, but the long-term prize (successful drug commercialization) still lies ahead – and it’s that prize that Genmab and hopeful Merus shareholders are ultimately after. (^[1]) (^[12])

Sources

1. https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-second-quarter-2025-and
2. https://ir.merus.nl/news-releases/news-release-details/merus-announces-financial-results-fourth-quarter-and-full-year-4
3. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-merus-therapy-treat-lung-pancreatic-cancers-2024-12-04/
4. https://partnertx.com/merus-and-partner-therapeutics-announce-license-agreement-for-the-u-s-commercialization-of-zenocutuzumab-in-nrg1-fusion-positive-cancer/
5. https://ir.merus.nl/news-releases/news-release-details/merus-and-partner-therapeutics-announce-license-agreement-us
6. https://ir.merus.nl/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and
7. https://cincodias.elpais.com/companias/2025-09-29/la-biotecnologica-genmab-comprara-merus-por-6824-millones-de-euros-para-hacerse-con-un-farmaco-oncologico.html
8. https://sec.gov/Archives/edgar/data/1651311/000095017024022055/mrus-20231231.htm
9. https://za.investing.com/news/analyst-ratings/wells-fargo-sets-91-target-on-merus-stock-cites-mcrc-potential-93CH-3543105
10. https://valuesense.io/ticker/mrus
11. https://mboum.com/quotes/MRUS
12. https://americanbankingnews.com/2025/10/01/merus-nasdaqmrus-downgraded-to-equal-weight-rating-by-wells-fargo-company.html
13. https://defenseworld.net/2025/10/01/merus-nasdaqmrus-rating-lowered-to-equal-weight-at-wells-fargo-company.html

For informational purposes only; not investment advice.